Must be 12 weeks from radiotherapy; if patients are within 12 weeks of radiotherapy, then the progressive lesion must be outside of the high-dose radiation target volume or have unequivocal evidence of progressive tumor on a biopsy specimen
ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Radiotherapy may be given before or after protocol treatment. when radiotherapy is planned prior to protocol treatment administration, patients must have completed adjuvant radiotherapy >= 2 weeks prior to randomization for protocol therapy, if applicable
Patients receiving adjuvant radiotherapy within 2 weeks prior to randomization
Patients who have had chemotherapy or radiotherapy within 2 weeks prior to starting radiation treatment
For participants treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, two weeks must have lapsed since last date of radiotherapy, which is recommended to be a limited field; participants who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed and two weeks have passed since the last date of therapy
Radiotherapy </= 28 days of enrollment. Patients must be recovered from all acute radiotherapy-related toxicities. No radiopharmaceuticals (strontium, samarium) within 8 weeks of enrollment
Participants who have received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowed
Patient has received chemotherapy or radiotherapy within 4 weeks prior to day 1 of study; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been radiated
Radiotherapy within 2 weeks of first dose of study drug
Chemotherapy or stereotactic radiotherapy within the last 2 weeks
Less than four weeks since last radiotherapy (excluding palliative radiotherapy).
Washout time of at least 4 weeks for prior biological, chemotherapeutic, or radiotherapy
Prior radiotherapy within 2 weeks of the first dose of study treatment
Radiotherapy: 6 weeks
Prior radiotherapy is acceptable provided it was applied within 4 four weeks before starting of this trial and the patient recovered from any radiotherapy related acute toxicities.
PHASE II INCLUSION CRITERIA: For patients who do not receive radiotherapy after chemotherapy, the randomization must occur within 6 weeks of the last chemotherapy cycle; the study treatment must start within 2 weeks from randomization; for patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy, the randomization must occur within 9 weeks of the last chemotherapy cycle but at least 2 weeks after completion of radiotherapy and the first dose of 177Lu-DOTA0-Tyr3-octreotate cannot be given within 8 weeks of radiotherapy
Has received prior radiotherapy within 2 weeks of therapy.
Participants who have had radiotherapy within 3 weeks
Prior radiotherapy or radiosurgery < 2 weeks prior to starting study treatment
Patients who have had radiotherapy within 4 weeks
Patients who have received radiation therapy within 3 weeks before transplant. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field
Thoracic radiotherapy to lung fields =< 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting INC280 is allowed
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Patients who have had radiotherapy =< 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
radiotherapy within 4 weeks prior to treatment with APS001F (intensive radiotherapy within 6 weeks or palliative radiotherapy within 2 weeks).
Patient who has received radiotherapy =< 4 weeks prior to study entry. Palliative radiotherapy for symptomatic control is acceptable (if completed at least 2 weeks prior to study drug administration and no additional radiotherapy for the same lesion is planned)
Patients must be 4 weeks beyond previous treatment of any chemotherapy or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity. Exception: Patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field. Patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents.
COHORT 3: ENDOMETRIAL CANCER: Patients who have undergone radiotherapy within 4 weeks of first dose of study treatment
Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs
Radiotherapy within 2 weeks of first dose of study medications
Radiotherapy to target lesions during study or within 2 weeks of enrollment
Patients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed per the following timelines:\r\n* Radiotherapy to the thoracic cavity or abdomen within 4 weeks prior to registration\r\n* Radiotherapy to bone lesions within 2 weeks prior to registration\r\n* Radiotherapy to any other site within 4 weeks prior to registration\r\n* NOTE: In all cases, there must be complete recovery and no ongoing complications from prior radiotherapy
Patients who have had radiotherapy within < 4 weeks are ineligible
Patients who have had radiotherapy within the last 4 weeks before the first OBP-301 administration.
Patients who have had chemotherapy or radiotherapy within 2 weeks of first dose of zydelig
No radiotherapy within 2 weeks
Patient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy­related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy­related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowed
Patient has received chemotherapy or radiotherapy within 4 weeks prior to day 1 of study; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been radiated
Patients must be >= 4 weeks beyond previous treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field; patients who have received non-chemotherapeutic biological agents will need to wait at least 5 half-lives or 4 weeks, whichever is shorter, from the last day of treatment of non-chemotherapeutic biological agents
Radiotherapy for primary HPVOC within 8 weeks, or radiotherapy for any other reason within 3 weeks prior to the first dose of vaccine
Patients who have had radiotherapy ? 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before registration; patients who received prior radiotherapy to >= 25% of bone marrow are not eligible independent of when it was received
Patient received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entry
CAPMATINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:\r\n* Any prior treatment with capmatinib, crizotinib, or any other cMET or HGF inhibitor\r\n* Thoracic radiotherapy to lung fields =< 4 weeks prior to starting capmatinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting capmatinib; palliative radiotherapy for bone lesions =< 2 weeks prior to starting capmatinib is allowed\r\n* Receipt of any anticancer or investigational agent within 4 weeks or =< 5 half-lives of the agent (whichever is longer) prior to the first dose of capmatinib; if previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before the first dose of capmatinib
Patient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowed
Any radiotherapy within 2 weeks of registration
Radiotherapy less than 2 weeks before the first dose of study treatment or have not recovered from acute toxic effects from radiotherapy.
Patient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowed
Patients who have had radiotherapy =< 4 weeks prior to starting study drug, or =< 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g., for analgesic purpose or for lytic lesions at risk of fracture)
Patients must be >= 4 weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field
Patients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative radiotherapy (XRT) (small port)
The patient must have undergone prior external beam radiotherapy to a dose of 54-60 Gy to the brain stem; at least 4 weeks but no more than 14 weeks must have elapsed from the completion of radiotherapy
Radiotherapy within the 2 weeks prior to initiation of treatment
Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass
At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to enrolment
Prior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative radiotherapy (to non-CNS disease) within 1 week
Prior radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatment
Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ? 25% of bone marrow are not eligible, irrespective of when it was received.
Thoracic radiotherapy to lung fields ? 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities
12 weeks from radiotherapy
Radiotherapy within the past 2 weeks prior to date of first administration of study drug
Radiotherapy ? 2 weeks prior to randomization. Patients must have recovered from all radiotherapy-related toxicities.
Concurrent radiotherapy or radiotherapy within 4 weeks prior to randomization or previous radiotherapy at the indicator sites (the sites that are to be followed for determination of a response)
Has received radiotherapy within the 28 days prior to first dose or within 12 weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control.
Radiotherapy or prior systemic chemotherapy within 2 weeks
Prior radiotherapy (RT) to current field of CNS disease ? 4 weeks
Radiotherapy within 4 weeks of protocol therapy
Patients may have had prior radiotherapy for metastatic disease as long as it was > 4 weeks prior to registration and the patient has recovered from adverse events associated with the radiotherapy
PHASE II: Patients may have had prior radiotherapy for metastatic disease as long as it was > 4 weeks prior to randomization and the patient has recovered from adverse events associated with the radiotherapy
At least 2 weeks since prior radiotherapy or stereotactic radiosurgery, and 4 weeks since prior major surgery at time of study enrollment
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
At least 4 weeks after surgery or radiotherapy
Radiotherapy within 2 weeks prior to study day 1.
Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs
Radiotherapy within 3 weeks prior to the first dose of lenvatinib.
Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.
Patients that have been treated with any of the following within 4 weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists and LHRH antagonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment).
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Previous radiotherapy within 2 weeks of starting study therapy.
Radiotherapy within 2 weeks of the first dose of study drug
Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass
Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administration
Prior radiotherapy within 2 weeks of study treatment
Patients who have received radiotherapy =< 4 weeks prior to registration, with the exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =< 1 are not eligible for participation\r\n* Note: any lesions treated with radiation therapy cannot be used in disease assessment
Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment
Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)
Radiotherapy < 3 weeks prior to the first planned dose of study treatment
Participants who have had radiotherapy within 4 weeks prior to study entry
Patients must be >= 4 weeks beyond treatment with any chemotherapy or radiotherapy, and must have recovered to =< grade 2 toxicity for any treatment-limiting toxicity of prior therapy; (exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, ribs, sternum, scapulae, vertebrae or skull were not included in the radiotherapy field); also, patients who have received non-chemotherapeutic biologic agents will need to wait at least five half-lives or four weeks, whichever is shorter, from the last day of treatment; exception: no washout of cetuximab or regorafenib is required for patients who have received prior cetuximab or regorafenib and have recovered from any treatment-related toxicities to grade =< 1
at least 8 weeks without tumor progression after any whole brain radiotherapy
Patients receiving any systemic chemotherapy or thoracic radiotherapy within 3 weeks prior to study treatment.
Radiotherapy, chemotherapy or immunotherapy within 4 weeks, or single fraction of palliative radiotherapy within 14 days of administration of enrollment
PART B: Prior radiotherapy to proposed target lesions is not permitted unless completed more than 4 weeks prior to treatment within the study and that there has been documented progression at these sites; radiotherapy to non-target lesions is permitted within 2 weeks of study entry provided all acute effects of the radiotherapy have resolved to =< grade 1
Patients who have received radiotherapy =< 2 weeks prior to starting treatment
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Prior full field radiotherapy =< 4 weeks or limited field radiotherapy =< 2 weeks prior to enrollment; patients must have recovered from all therapy-related toxicities; the site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease
Radiotherapy within 4 weeks prior to first dose of FOLFIRI
No prior treatment except for local radiation or a short course of steroids for control of symptoms; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Radiotherapy within 2 weeks
Any whole brain radiotherapy (WBRT) was completed at least 2 weeks prior to the first dose of study drug.
Subjects who have received systemic antitumor therapy within 4 weeks or radiotherapy to target lesions within 3 weeks before the first dose of study drug, which is longer
Radiotherapy within 4 weeks before enrollment.
Radiotherapy within 4 weeks before enrollment.
Any major surgery, radiotherapy or immunotherapy within the 4 weeks prior to first dose of study drug, or palliative radiotherapy to a single symptomatic lesion within the 2 weeks prior to first dose of study drugs.
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Patients who received radiotherapy within 4 weeks of entry
Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs
Prior radiotherapy within 2 weeks prior to first dose of study drug
Less than three weeks since the last radiotherapy dose
Participants who have received radiotherapy less than 2 weeks prior to first dose of study medication
Discontinuation of all other therapies (including other investigational drugs, radiotherapy, or chemotherapy) for the treatment of cancer ?4 weeks (?6 weeks if nitrosoureas, ?12 weeks if radiotherapy) before initiation of study treatment
Subject has had radiotherapy or surgery within the 4 weeks prior to treatment with ASP4132.
Patients treated with local radiotherapy with or without a brief (2 weeks or less) exposure to steroids are eligible; patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy
Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Patients who have had radiotherapy =< 4 weeks prior to starting study drug, or =< 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities
An interval of at least 6 weeks between prior surgical resection, 4 weeks from the end of prior radiotherapy
Radiotherapy or systemic therapy within 2 weeks of baseline
Patients who have received radiotherapy within =< 4 weeks prior to registration
Last radiotherapy treatment 4 weeks prior to starting treatment with this protocol – with the exception of palliative radiotherapy – and there must be sites of measurable disease that did not receive radiation
Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited radiotherapy within the last 2 weeks.
Radiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial treatment
Patient who has received thoracic radiotherapy to lung fields =< 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =< 2 weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting study treatment is allowed
Prior radiotherapy is allowed, provided at least 2 weeks have elapsed from completion of radiotherapy to initiation of protocol treatment
Radiotherapy less than 3 weeks before the first dose of study treatment. If prior radiotherapy occurred <4 to 6 weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC.
Prior surgery or radiotherapy (RT) within 2 weeks of study entry
Prior surgery or radiotherapy (RT) within 2 weeks of study entry
No concurrent use of chemotherapy or radiotherapy (radiotherapy should be completed at least 4 weeks from study entry)
Radiotherapy within 4 weeks or less prior to starting first veledimex dose
Subjects may not have received prior radiotherapy to the index lesion within 4 weeks
Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for bevacizumab) of liver resection
Radiotherapy less than 3 weeks before the first dose of study treatment.
Radiotherapy to the bone marrow within 6 weeks prior to enrollment OR within3 months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least 60% of the pelvis was received; within 2 weeks prior to enrollment if local palliative radiotherapy was received.
Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Patient must not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields except patients who have progressed following stereotactic radiosurgery for 1-3 brain metastases, with at least one new lesion
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields in such a way that curative intent with radiation cannot be met
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), that would result in overlap of radiation fields.
Prior receipt of ipsilateral breast or chest wall radiation that would result in significant overlap of radiation therapy fields; prior contralateral radiotherapy for breast cancer is allowed
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
Patients may not have had prior radiotherapy (> 30 Gy) to the area requiring treatment that would result in any overlap of tissue in both fields
Prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer.
Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation fields
Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields
Prior radiation therapy to the head or neck resulting in overlap of radiotherapy (RT) fields
Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in significant overlap of radiation fields
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Prior radiation, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy (RT) fields
Prior radiation therapy resulting in overlap of radiation therapy (RT) fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiation therapy to the abdomen that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields
Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in direct overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.
Patients who received prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy treatment volumes
Prior abdominal radiotherapy that would result in overlap of fields; the treating radiation oncologist should review prior radiation therapy (RT) fields as available
No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields
History of prior malignancy is acceptable, but prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields is not allowed
Prior radiotherapy to the region of the body that would result in overlap of RT fields with the current protocol treatment
Prior neck and/or upper thoracic radiotherapy that would cause an overlap of treatment fields
Prior chemotherapy or radiosensitizers for cancer of the head and neck (except for T1 glottic cancer) that would result in an overlap of radiation fields.
Prior radiation therapy to the head or neck, which would result in overlap of radiation therapy fields
Patient must not have had any prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer:\r\n* Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant’s prior and current course of radiation therapy, radiotherapy was completed more than four weeks from first fraction of proton therapy administered in this study, and the participant has recovered to grade =< 1 toxicity related to prior radiotherapy
Patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy that would overlap the anticipated study treatment fields
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy that overlaps with radiation fields
Prior abdominal radiation therapy with fields overlapping the current fields
Prior history of radiation therapy that would lead to overlap with new radiation fields
Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease\r\n* NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist\r\n* NOTE: Patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment\r\n* NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol
Obtained within 14 days prior to treatment start: Platelets (UNVPLT) >= 100 × 10^9/L
Prior isotope therapy with strontium-89, samarium or radium-223 within 12 weeks of treatment start
Administration of antifungal agents (itraconazole, fluconazole, etc) within 4 weeks of treatment start or unrecovered adverse events (AEs) due to agents administered more than 4 weeks of treatment start
Prior or concomitant treatments:\r\n* Prior treatment with ibrutinib\r\n* The following cancer treatments:\r\n** Chemotherapy or biological therapy within 14 days prior to start of treatment\r\n** Immunological therapy, radiation therapy, or hormonal therapy within 7 days prior to start of treatment\r\n** Major surgery within 15 days prior to start of treatment\r\n** Subjects who have unresolved toxicity (>= grade 2) from prior anti-cancer therapy, unless that event is thought to be due to disease progression\r\n* Any investigational agent, including small molecule agents, within 30 days prior to start of study treatment\r\n* Any of the following with 7 days prior to start of study treatment:\r\n** B-cell receptor pathway inhibitor;\r\n** CYP3A inhibitors (such as fluconazole, ketoconazole, and clarithromycin);\r\n** Potent CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine or St. John's wort);\r\n** Warfarin or requires the use of warfarin (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of this effect);\r\n** Antiretroviral medications\r\n** Antibiotics, antifungals, or antivirals to treat an active infection (prophylactic antibiotics allowed)\r\n* Subjects who are unable or unwilling to discontinue use of prohibited medications, including medications with CYP450 interactions\r\n* Subject has received prior treatment with allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication
Patients must be enrolled before treatment begins; the date protocol therapy is to start must be no later than 42 days from the time of recurrence and within 7 days from enrollment
Must start the study treatment no more than 60 days from the last dose of RT (if administered) and no more than 120 days from the date of surgical removal of nodal metastases
Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs (e.g. cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to start of the study treatment (day 1 [D1] of cycle 1)
Receipt of a stable ART regimen for at least 3 weeks prior to start of trial
Patients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of the treatment and/or for at least 5 days before starting treatment
Prior radiation within 14 days before start of study registration
All radiology studies (study requiring staging) must be performed within 35 days prior to the start of therapy
Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.
Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.
Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).
Have had significant active cardiac disease within 6 months prior to the start of study treatment, including any of the following:
Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment
Measurable disease before start of pre-study nivolumab treatment
Hematologic inclusion within 2 weeks of start of treatment
< 24 days from prior temozolomide, < 6 weeks from nitrosourea, < 4 weeks from other chemotherapy or investigational agents prior to start of treatment within study.
Concomitant therapies that cannot be discontinued or switched to a different medication prior to study entry that are known to increase serum phosphate levels are not permitted within 4 weeks prior to start of study treatment)
Patients must be maintained on a stable corticosteroid regimen from the time of their baseline scan until the start of treatment and/or for at least 5 days before starting treatment
Emergent radiation therapy, one dose of intrathecal chemotherapy, and up to 7 days of steroids for treatment of relapse are permitted before start of treatment in participants who relapse after completion of frontline therapy
Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start
Patients must be able to start treatment (androgen suppression [AS] or radiation) within 120 days of study registration
Systemic therapy with immunosuppressive agents within 7 days before the start of treatment; or use of any investigational drug within 28 days before the start of trial treatment.
Subjects with concurrent cytotoxic chemotherapy or radiation therapy; there must be at least 28 days between any other prior chemotherapy (or radiotherapy) and study treatment; prior antibody therapy must be discontinued 8 weeks prior to start of study treatment
Administration of an investigational therapeutic within 30 days of treatment start
Systemic therapy with immunosuppressive agents within 7 days before the start of treatment; or use of any investigational drug within 28 days before the start of trial treatment.
Prior anti-ROR1 therapy within 12 weeks prior to the start of study therapy.
Has received prior RT within 2 weeks of start of study treatment
Patients should be off any prior treatment or line of therapy for 2 weeks prior to start study with the exception of hydrea (hydroxyurea)
Patients must start therapy within 7 calendar days of registration
Baseline pulmonary function tests (PFTs) available or will be obtained prior to treatment start
Prior chemotherapy or radiation must have concluded >= 21 days prior to the start of study treatment
Change in chemotherapy or hormone therapy within 8 weeks of the start of the study
STUDY TREATMENT: Able to start study treatment in less than or equal to 90 days after completion of chemoradiation
Subjects must be scheduled for surgery at Medical University of South Carolina (MUSC) no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1
Agreement to use adequate contraception from 2 weeks before the start of treatment with Minnelide and until 90 days after completion of treatment.
Prior radiation treatment less than 6 months from the planned start of reirradiation of any part of the intended treatment volume
Concurrent anticancer treatment within 28 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy], immune therapy, or cytokine therapy except for erythropoietin); major surgery within 28 days before the start of trial treatment (excluding prior diagnostic biopsy); concurrent systemic therapy with immunosuppressive agents within 28 days before the start of trial treatment; use of hormonal agents within 7 days before the start of trial treatment; or use of any investigational drug within 28 days before the start of trial treatment; Note: subjects receiving bisphosphonate or denosumab are eligible provided treatment was initiated at least 14 days before the first dose of avelumab
Patients may be enrolled in any line of standard treatment (without investigational agents); the start date of current treatment should be at least two 2 weeks or more prior to registration; (Note: patients will continue to receive the planned active treatment with chemotherapy or endocrine therapy [standard of care] and initiate denosumab at the recommended dose for this protocol)
Cancer chemotherapy within 2 weeks prior to start of daratumumab treatment (exception hydroxyurea). Use of hydroxyurea to control proliferative disease will be allowed prior to starting therapy on study and for 7 days during cycle 1-3 (maximum daily dose of 7 gm)
Surgery, radiation or chemotherapy within 4 weeks of proposed step 1 start date
Investigational drug within 4 weeks of proposed step 1 start date
Long-acting somatostatin analogue treatment within 14 days of proposed step 1 start date
Prior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:
Any investigational therapy within 28 days prior to the start of Cycle 1
Hemoglobin (Hgb) >= 9 g/dL, within 14 days start of study start
Serum total bilirubin =< 1.5 x ULN, within 14 days start of study start
Subjects who have received therapy for HCV =< 4 weeks from the start of pembrolizumab; Note: those with untreated HCV and those who completed HCV therapy >= 4 weeks of study treatment start are eligible
Serious persistent infection within 14 days prior to the start of study medication.
Radiation therapy within 4 weeks prior to start of olaparib treatment (includes radiation targeting bone metastases) or radionuclide treatment within 6 weeks of treatment start.
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must be off chemotherapy for a minimum of 3 weeks prior to start of treatment; targeted therapies must be stopped at least 3 days prior to start of lymphodepletion
Prior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at doses of ?20 mg/day, G-CSF or GM CSF are permitted up to 2 weeks prior to start of study treatment.). Note: excluding pre-treatment with rituximab as part of this study
Patients must not have received chemotherapy and/or radiation therapy within 2 weeks of start of protocol treatment; hydroxyurea is allowed up to 48 hours prior to starting therapy in the setting of rapidly proliferating disease
At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 1
Prior treatment with chemotherapy or immunotherapy within 14 days prior to enrollment. Subjects receiving palliative radiation to CNS disease within 7 days may be eligible with PI approval. If the most recent treatment line is an EGFR-TKI, the washout period is a minimum of 3 days before the start of paclitaxel/selumetinib (i.e. treatment with the EGFR-TKI may continue until 3 days before start of study treatment). For other targeted therapy agents, the washout period will be 5 half-lives, prior to start of treatment on study.
Study treatment both planned and able to start within 7 days of randomisation.
Hormonal treatment within 2 weeks prior to start of study treatment
Patients must be registered prior to the start of treatment
The date protocol therapy is projected to start must be no later than 7 days after the date of study registration
Prior treatment of cancer (chemotherapy, radiation therapy, and surgery) is allowed if completed at least 3 weeks prior to start of treatment with nintedanib and if all treatment-related toxicities are resolved
Flucytosine within 2 weeks prior to start of study treatment
For patients receiving treatment of their AML, MDS or ALL prior to transplantation:\r\n* Interval between the start of a cycle of conventional cytotoxic chemotherapy and the start of conditioning regimen must be at least 30 days\r\n* Interval between completing treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and the start of conditioning regimen must be at least 10 days
Patients must not have received prior chemotherapy or radiation for < 4 weeks prior to start of study treatment
Patients may be entered if they have received prior radiation therapy involving =< 30% of the bone marrow; any prior radiation therapy must have been administered >= 4 weeks prior to start of study treatment and the patient must be recovered from the acute toxic effects of the treatment prior to start of study treatment
Platelets >= 100,000 cells/uL (to be performed within 7 days prior to start of study treatment)
At least 2 weeks from prior MF-directed treatment (till the start of study drug)
Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.
Patient must have a history and physical within 2 weeks prior to the start of any protocol therapy (radiation and veliparib)
Patients must have been off all prior therapy for CML for 2 weeks prior to start of study therapy and recovered from the toxic effects of that therapy; exceptions to these are hydroxyurea and TKIs (including but not limited to imatinib, nilotinib, and bosutinib) which should be discontinued >= 24 hours prior to the start of therapy; patients who are receiving dasatinib prior to enrollment do not have to discontinue this agent prior to start of study therapy
Participants who have had chemotherapy or radiotherapy within 2 weeks prior to treatment start or those who have not recovered from adverse events due to agents administered more than 2 weeks prior to treatment start; hydroxyurea is allowed for symptomatic leukocytosis during screening, lead in, and cycle 1 only if clinically necessary; a total white blood cell (WBC) count < 25 x 10^9/L prior to first dose of decitabine on trial is required; prior leukapheresis and/or prior or concurrent treatment with hydroxyurea to achieve this level are allowed
Prior hypomethylating agent (HMA) therapy is allowed, however this study excludes: (1) patients whose relapse occurred on HMA-based therapy immediately prior to this study and (2) patients who experience disease progression (see definition below) while receiving HMA-based therapy within the last 12 weeks prior to treatment start on study; disease progression is defined as either: (1) patients with MDS who have evidence of initial progression to AML (defined by the presence of >= 20% blasts in peripheral blood or bone marrow) while receiving HMA-based therapy within the last 12 weeks prior to treatment start on study; OR (2) patients with AML who have evidence of progressive disease according to European Leukemia Net (ELN) 2017 criteria (e.g. > 50% increase in marrow blasts over baseline or > 50% increase in peripheral blasts to > 25 x10^9/L [> 25,000/uL] [in absence of differentiation syndrome]) while receiving HMA-based therapy within the last 12 weeks prior to treatment start on study\r\n* (Note: Patients who relapse post-transplant who received HMA treatment prior to transplant are eligible for study)
Patients must be registered prior to the start of treatment
The date protocol therapy is projected to start must be no later than 7 days after the date of study registration
Prior radiation treatment less than 3 months from planned start of re-irradiation of any part of the intended treatment volume
Normal left ventricular function as evaluated by echocardiograph within 4 weeks of start of protocol therapy
Must be willing to provide blood samples prior to the start of treatment on this study for exploratory tumor molecular profiling analyses.
Cancer chemotherapy within four weeks prior to start of MCLA-117;
Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment.
Concurrent anti-cancer chemotherapy, except TACE (transarterial chemoembolization), during or within 30 days prior to start of study drug
Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within 2 weeks prior to the start of study treatment (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within 4 weeks prior to the start of study treatment, with the following exceptions:
Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment
Patients with proliferative disease can be cytoreduced with cytotoxic chemotherapy at investigator’s discretion, but there should be at least a 14 day window between start of cytoreductive therapy and start of daratumumab
Study treatment both planned and able to start within 14 days of randomisation
Last dose of any myelosuppressive or biologic therapy was given at least 2 weeks before the start date for vorinostat on this protocol
Patients who have received chemo-, hormone-, radio or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 14 days prior to start of treatment or those who have not recovered from adverse events attributed to the agent to grade 1 or baseline\r\n* Exceptions for prior treatments are:\r\n** Hydroxyurea for increased blast count (no washout period required; it can be continued throughout the first cycle of therapy)\r\n** Leukapheresis for leukocytosis (no wash out period required; it can be continued during the study)\r\n*** Note: If patient is registered prior to completion of washout, start date of treatment will need to be confirmed prior to registration; please see assigned quality assurance monitor (QAM) with questions
Therapy for underlying malignancy within 2 weeks prior to start of study treatment
Cancer immunotherapy within four weeks prior to start of daratumumab treatment (exception blinatumomab within two weeks prior)
Chemotherapy or surgery within 4 weeks prior to treatment start
Radiation treatment within 3 weeks prior to treatment start
Chemotherapy or surgery within 4 weeks prior to treatment start
Radiation treatment within 3 weeks prior to treatment start
Have had significant active cardiac disease within 6 months prior to the start of study treatment
No active symptoms related to carcinoid syndrome during the last 3 months prior to start of study treatment.
Pretreatment with interferon as last treatment prior to start of study treatment.
Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to the start of the study treatment
Cohort 1a & 1b patients only: an interval of at least 3 weeks between prior surgical resection to start of study therapy, or one week for stereotactic biopsy to start of study treatment
Platelets >= 100 000/uL, specimens must be collected within 10 days prior to the start of study treatment
Subjects who have received systemic anticancer therapy within 3 weeks before the start of study treatment; mitomycin C or nitrosoureas must be excluded within 6 weeks before the start of study treatment
Use of drugs that inhibit renal tubular secretion (e.g. probenecid and cimetidine) within 2 weeks before the start of study treatment
No brain radiation therapy > 4 weeks before planned start of protocol treatment
No chemotherapy for > 3 weeks before planned start of protocol treatment
History of any of the following within 6 months prior to start of MLN0128:
Treatment with any systemic chemotherapy or investigational agents within 3 weeks of the start of study treatment; endocrine treatment must be stopped prior to initiating study treatment; subjects must have recovered from toxicities of prior therapy
More than one relapse, secondary glioblastoma and prior treatment with bevacizumab are excluded. An interval of at least 12 weeks from the completion of radiation therapy to start of study treatment is required.
Receipt of any experimental treatment within 30 days of start of treatment with afatinib until the end of treatment visit
If PET-negative based on the returned results from centralized review, patients must be planning to begin further treatment within 35 days of the start of cycle 3 of R-CHOP; if PET-positive based on the returned results from centralized review, it is important for patients to start IFRT as soon as possible after the end of cycle 3 of R-CHOP; they should be planning to initiate IFRT followed by yttrium-90 ibritumomab tiuxetan within 35 days of the start of cycle 3 of R-CHOP
Central review of pathology is required for study participation, but not required prior to enrollment or start of treatment in order to avoid delay. If the results of central pathology review are not available prior to the start of study treatment, the confirmation of diagnosis of ATC at the local laboratory is mandatory prior to scheduled start of treatment with lenvatinib.
Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice
Chemotherapy within 21 days or at least 5 half-lives prior to the planned start of study treatment; radiation outside the thorax within 14 days prior to the planned start of study treatment or thoracic radiation; antibody based therapy or investigational therapy within 28 days prior to the planned start of study treatment.
Last dose of therapeutic glucocorticosteroids given greater than 14 days prior to start of study treatment.
serious persistent infection within 14 days prior to the start of study medication;
Therapy for underlying malignancy within 2 weeks prior to start of study treatment:
Subject is taking warfarin at start of treatment or within 6 months prior to start of study treatment
Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
Radiation therapy within four weeks prior to start of study treatment (day -1)
Received chemotherapy or biologic therapy =< 3 weeks prior to the start of neratinib
The interval between last PD-(L)1 directed treatment and start of study treatment should be at least 21 days.
Systemic therapy with immunosuppressive agents within 7 days before the start of trial treatment; or use of any investigational drug within 28 days before the start of trial treatment
Subjects who have started oral or parenteral anticoagulation therapy within 2 weeks before the start of anetumab ravtansine until end of treatment visit.
Completion of all therapy for the treatment of cancer 2 weeks before the start of study therapy and recovered.
Study treatment both planned and able to start within 7 days after randomisation.
Radiation therapy planned to start =< 8 weeks after surgery and at least 7 days after the start of minocycline
Patients with a history of prior intratumoral bleeding must be evaluated with a non-contrast head CT to exclude acute blood prior to start of treatment
Patients who have required a blood transfusion within 28 days prior to study start
Participants who received any investigational treatment within 4 weeks of study start
Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment
Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.
Completion of previous chemotherapy regimen >= 2 weeks prior to the start of study treatment
Administration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to of the first dose of study drug; in the event of rapidly proliferative disease use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment.
Laboratory evaluations;\r\n* Semen analysis (patients will not be excluded if they do not wish to have an analysis or their insurance denies the claim) (prior to start of radiation)\r\n* Follicle-stimulating hormone (prior to start of radiation\r\n* Luteinizing Hormone (prior to start of radiation)\r\n* Lactate Dehydrogenase (prior to start of radiation)\r\n* Human chorionic gonadotropin (prior to start of radiation)\r\n* Complete blood count (prior to start of radiation)\r\n* Alpha-fetoprotein (prior to start of radiation)
No prior radiation treatment to the affected spine, or sacral region; prior chemotherapy is allowed within 30 days of start of treatment
Regular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1
Concurrent anticancer treatment (e.g., cytoreductive therapy, radiotherapy except for palliative bone-directed radiotherapy, immune therapy, or cytokine therapy except for erythropoietin) within 28 days before start of trial treatment; major surgery within 28 days before start of trial treatment (excluding prior diagnostic biopsy); use of hormonal agents within 7 days before start of trial treatment, except for subjects with castration-resistant prostate cancer (CRPC), who may remain on treatment with luteinizing hormone-releasing hormone agonists or antagonists; or use of any investigational drug within 28 days before start of trial treatment. Note: Small molecule or antibody targeted therapy is permissible <14 days from start of trial treatment.
Chemotherapy within 14 days of the start of this trial
For patients with no prior chemotherapy, treatment must start within 35 days of\r\ndefinitive surgery or as indicated if enrolled on therapeutic study
Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
Prior treatment with bendamustine (within 2 years of the start of Cycle 1)
Must be able to start treatment with radiation therapy (RT) within 2 weeks or 10 working days at a qualified center (to be defined by the Radiation Oncology chair) and to start TMZ prescribed at a participating center within 2 weeks or 10 working days of randomization
Any investigational treatments for any condition within 4 weeks prior to the start of study treatment.
Eligible for and agree to BM aspirate prior to treatment start
No prior treatment for ALL, except steroids or hydroxyurea (stopped within 24 hours before start of protocol treatment)
Treatment must start not more than 15 days from diagnosis of metastatic retinoblastoma
At least 4 months from prior anti-EGFR therapy prior to start of study treatment
Patients must have been off all prior therapy for CML for 2 weeks prior to start of study therapy and recovered from the toxic effects of that therapy; exceptions to these are hydroxyurea and TKIs (including but not limited to imatinib, nilotinib, dasatinib, ponatinib and bosutinib), which should be discontinued 48 hours (hrs) prior to the start of therapy; patients who are receiving nilotinib prior to enrollment do not have to discontinue this agent prior to start of study therapy
Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to the start of the study treatment (i.e., D1 of Cycle 1)
History of heart problems or thrombosis within 6 months prior to study start.
Concomitant or recent treatment with other investigational drug (within 4 weeks or 5 elimination half life times prior to anticipated start of study treatment).
3. Patients must start treatment in the extension protocol within 8 weeks of their last injection administered in the core protocol.
Patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatment
Any prior anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 21 days prior to start of CA-4948
Treatment with any chemotherapy or investigational agents within 4 weeks of the start of study treatment; subjects must have recovered from toxicities of prior therapy
No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment
One of the following:\r\n* Cytotoxic chemotherapy, alemtuzumab, or an adequate course of 5-azacitidine or decitabine within 3 months prior to start of conditioning; or\r\n* Previous BMT within 6 months prior to start of conditioning\r\n** Note: Patients who have received treatment outside of these windows may be eligible if it is deemed sufficient to reduce graft rejection risk; this will be decided on a case-by-case basis by the PI or co-PI
PRIOR TO START OF TREATMENT:
Prior systemic treatment with an azole drug within two weeks of start of treatment
Will not start treatment for at least 2 weeks AND
Unable to start nintedanib/placebo treatment between 4 - 6 weeks after completing the last dose of thoracic radiation
Patients planning to start any type of cancer therapy during the 8 week, double blind, course of the study, once randomized on the study
An episode of vomiting or retching within 24 hours before the start of the initial treatment with chemotherapy
Received any investigational treatment within 4 weeks prior to the start of study medication;
Patients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea or ruxolitinib, which may be continued until start of conditioning therapy
Patient has hemodynamic instability within 24 hours before the start of study treatment.
Patient used any medication that increases the risk of bleeding within 24 hours before the start of study treatment.
Willingness to be randomized to an immediate or delayed (by 8 weeks) start date
In patients without cGVHD, transplant must have occurred 80-150 days before the start of study drug
Participants take supplements or foods that are labelled as containing green tea for 8 weeks before start of treatment
Intention to start therapy
Platelets >= 100,000/L, within 2 weeks prior to study start
Patients are eligible to be treated with RT and plan to start treatment
Treatment with investigational or approved anti-cancer drugs within 4 weeks before the start of BAY1436032 treatment and during the study (glioma patients must have completed chemoradiotherapy at least 12 weeks prior to screening and their baseline scan; see inclusion criteria #2)
Any prior therapy must have been completed >= 4 weeks or, if known, >= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior definitive radiation should have been completed >= 4 weeks or palliative radiation should have been completed >= 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels (patients on study may be eligible for palliative radiotherapy to non-targeted lesions after 2 cycles of therapy at the principal investigator [PI]’s discretion); patients who have had prior monoclonal antibody therapy must have completed that therapy >= 6 weeks (or 3 half-lives of the antibody, whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment); patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center PI, with a screening echocardiogram
Enrolled on SJMB12 and completed protocol directed radiation therapy
All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration\r\n* All triple negative patients must receive chemotherapy of the treating physician’s choice\r\n* ER/PR+ patients must receive chemotherapy (of the treating physician’s choice) unless Oncotype Dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine therapy alone\r\n* Patients may have breast reconstruction during protocol participation, but definitive breast cancer surgery must be completed at least 21 days prior to registration\r\n** Concomitant biologic therapy, hormonal therapy, and bisphosphonates are acceptable
Patients must have completed any prior radiation therapy and hormonal therapy at least 14 days prior to registration
Any prior surgeries must have been completed at least 4 weeks prior to randomization
Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to registration:\r\n* Chemotherapy/ targeted oral therapy administered in a daily or weekly schedule must be completed >= 1 week prior to registration; \r\n* Any chemotherapy administered in an every 2 week or greater schedule must be completed >= 2 weeks prior to registration\r\n* Additionally, patients should be recovered to equal to or less than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to any prior treatment, unless adverse event (AE)(s) are clinically nonsignificant and/or stable on supportive therapy
Prior ipilimumab treatment with the exception of adjuvant treatment completed ?6 months prior to enrollment
Must have completed definitive treatment that included surgical removal of the clinically detected MCC metastases (with/without adjuvant radiation therapy as determined by the treating investigator)
History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed >6 months prior and/or bone marrow transplant >2 years prior to first dose of rucaparib).
Prior treatment including chemoembolization or other ablative therapy, any cytotoxic, biologic or other investigational agents must have been completed at least 4 weeks prior to study entry
Previous chemotherapy/radiotherapy/targeted therapy should have been completed at least 4 weeks prior to start of FID-007 administration
Subjects must have completed systemic therapy at least 28 days prior to first dose.
Any prior therapy must have been completed >= 4 weeks (6 weeks for nitrosoureas and mitomycin C) or, if known, >= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; prior definitive radiation should have been completed >= 4 weeks or palliative radiation should have been completed >= 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI’s) discretion, and should have recovered to grade 1 or baseline from any toxicities
Previous immunotherapy/monoclonal antibody use must be completed at least 4 weeks or 4 half lives, whichever is longer prior to administration of TAK-580; in addition, radiation therapy to the target lesion must be completed at least 6 months prior to administration of TAK-580; all associated toxicity from previous therapies must be resolved to ? grade 1 or considered baseline prior to administration of TAK-580
Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.
Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
PHASE II INCLUSION CRITERIA: Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
Prior systemic radiation therapy (either IV, intrahepatic or oral) completed at least 4 weeks prior to study drug administration.
Prior focal radiotherapy completed at least 4 weeks prior to study drug administration.
Platelets >= 100,000/microliters, completed within 14 days prior to the date of registration
Participants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration
Previous radiation therapy completed =< 7 days prior to the start of study drugs
Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least 3 weeks prior to enrollment; if the irradiated area is the only site of disease, there will be progressive disease
Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least three weeks prior to enrollment; if the irradiated area is the only site of disease, there must be evidence of progressive disease
Prior radiation therapy must be completed >= 2 weeks prior to enrollment and the patient must have recovered from all toxicity; prior radiopharmaceuticals (strontium, samarium, alpharadin) must be completed >= 4 weeks prior to enrollment
Prior radiation therapy must be completed at least 14 days prior to registration for protocol therapy
Patients who have completed focal radiotherapy within 14 weeks from time of enrollment are eligible.
Time from prior therapy:\r\n* Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for nitrosoureas or mitomycin C)\r\n* Hormonal therapy is not considered anti-neoplastic therapy\r\n* Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
Prior therapy, including everolimus, octreotide, surgery, chemoradiation, is all permitted after being properly noted; this prior therapy must have been completed at least 28 days prior to study enrollment
Must have completed prior chemotherapy or radiation therapy at least 2 weeks prior to registration
Subjects may have previously treated brain or central nervous system (CNS) metastasis with radiation completed at least 2 weeks prior to registration; prior radiation to places other than CNS disease must be completed at least 14 days prior to registration; any number of prior radiation therapy regimens is allowed provided all toxicity of prior therapy is resolved to grade 1 or less.
Any prior therapy must have been completed at least 4 weeks prior to entry into the study
Prior radiation therapy is permitted, provided it is completed at least 28 days prior to the start of study drug
Prior radiation therapy must be completed at least 2 weeks prior to study enrollment
Prior chemotherapy, monoclonal antibody therapy, must have been completed at least 4 weeks prior to start. Radiotherapy or radiosurgery must have been completed at least 2 weeks prior to start.
Patients who have received radiation therapy must have completed this at least 4 weeks prior to starting therapy with cabozantinib, with the following exceptions:\r\n* Local radiation therapy to enhance bone healing of a pathologic fracture may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib\r\n* Local radiation therapy to treat post-fracture pain that is refractory to analgesics may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib
Prior systemic chemotherapy or other investigational therapy must have been completed at least two weeks prior to administration of nivolumab
(For cohort A only): Time from prior therapy: a. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. b. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
Prior radiation therapy is allowed if completed at least 14 calendar days prior to registration
Prior cetuximab permitted if it was given for no more than 9 doses in combination with radiation therapy or chemoradiation therapy for initial treatment of locally advanced or metastatic disease and completed at least 4 months prior to study enrollment
Previously received at least one line of prior systemic therapy for metastatic disease; if the patient has a sensitizing EGFR mutation or ALK rearrangement, the patient must have received at least one prior targeted therapy for metastatic disease (ie, EGFR tyrosine kinase inhibitor [TKI] therapy or ALK TKI therapy, respectively); there is no limit on prior therapies allowed; patients must have completed previous treatment (including other investigational therapy) in greater than or equal to the following times prior to initiation of trial treatment:\r\n* Anti-cancer monoclonal antibody (mAb) therapy must be completed >= 3 weeks prior to trial treatment\r\n* Chemotherapy administered in a daily or weekly schedule must be completed >= 1 week prior to trial treatment\r\n* Chemotherapy administered in an every 2-week schedule must be completed >= 2 weeks prior to trial treatment\r\n* Chemotherapy administered in an every 3-week schedule must be completed >= 3 weeks prior to trial treatment\r\n* Targeted small molecule therapy must be completed >= 1 week prior to trial treatment OR\r\n* Have not received prior systemic therapy for their cancer in recurrent or metastatic setting, AND have a tumor with tumor proportion score (TPS) >= 50% as measured by 22C3 PD L1 immunohistochemistry (IHC) test, AND no evidence of a sensitizing EGFR mutation or ALK rearrangement
Patients who have had cranial radiation therapy need to have completed it >= 8 weeks prior to enrollment
Radiotherapy completed within 2 weeks prior to treatment initiation; radiotherapy completed > 2 weeks prior to treatment initiation is allowed if all procedure-related toxicities resolved
Participants in cohort D must have completed systemic therapy AND have completed either consolidation thoracic radiotherapy or PCI or both completed either consolidation thoracic radiotherapy or PCI or both; participants in cohort D must initiate therapy with pembrolizumab within 6 weeks of the last dose of radiation; therapy must not start within 2 weeks from the last dose; consolidation radiotherapy dose must NOT be more than 3000 cGy; participants in cohort D must not have had progression of disease prior to the start of therapy
Prior radiotherapy completed <28 days before study enrollment.
Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study medication.
Prior locoregional therapy is allowed if completed at least 2 weeks prior to enrollment
Prior chemotherapy is allowed if stopped/completed at least 2 weeks prior to enrollment
Radiation therapy must be completed at least 2 weeks prior to study entry; radiated lesions may not serve as measurable disease unless they have been radiated >= 12 months prior to enrollment
Radiation therapy with >= 45 Gy tumor dose, completed >= 8 weeks prior to study entry
Prior therapy(ies), if applicable, must be completed according to the criteria below:
All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon >= 28 days before study entry
Patients should not have received prior systemic therapy for metastatic RCC; prior radiotherapy must have been completed at least 2 weeks prior to the administration of study drug; patients must be 2 weeks from prior major surgery and 1 week from pre-treatment biopsy; prior systemic adjuvant therapy (excluding with PD1 or CTLA4 pathway blockers) is allowed if treatment completed > 12 months previously
Previous treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least 1 year prior to enrollment\r\n* No prior talimogene laherparepvec or tumor vaccines allowed\r\n* No prior radiation to the same tumor bed allowed
Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment
Patient must have completed any systemic therapy regimens (except an ALK inhibitor) and therapeutic radiation a minimum of 21 days prior to initiation of study therapy
Patients must have failed external beam radiotherapy >= 5,000 cGy to the brain, and if eligible and tolerated, undergone appropriate treatment with temozolomide chemotherapy; all radiation and additional chemotherapies must have been completed at least 4 weeks prior to enrollment; prior therapy with nitrosoureas must have been completed at least 6 weeks prior to enrollment
Prior radiation therapy completed >= 4 months, and/or chemotherapy completed >= 1 month before study entry, and patient should have recovered from any adverse effects
Patients must have had at least one prior chemotherapeutic regimen; steroids alone and local radiation do not count as regimens; radiotherapy must have been completed at least 4 weeks prior to entry into the study; Rituxan alone does not count as a regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have completed radioimmunotherapy (RIT) > 12 months prior to enrollment
Completed all prior therapies (immunosuppressive medications, antineoplastic therapy, vaccination, immunotherapy, chemotherapy, radiotherapy, major surgery, etc) >4 weeks prior to the first study dose of medication (alemtuzumab ? 6 months).
PART II: All eligibility requirements and exclusion criteria as described in PART 1 must be fulfilled within 14 days of receiving subsequent doses; testing completed from Part 1 may be accepted as long as completed within this time frame (+/- 1 day)
radiation therapy (gamma knife) was completed ? 4 weeks prior to baseline
surgery was completed ?4 weeks prior to baseline
Prior cancer therapy with pemetrexed/cisplatin must have been completed at least 30 days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the bone marrow) must have been completed at least 30 days prior to study enrollment.
Prior cancer therapies not completed within 30 days prior to the first cycle of milataxel; radiotherapy completed less than 30 days prior to study enrollment; patients not recovered from radiation-related toxicities; patients receiving any concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an investigational agent while on-study; patients with greater than 2 prior radiotherapy treatments.
Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy )
Completed the following investigations
Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry
Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
Prior anti-cancer therapy or radiation therapy within 2 weeks prior to enrolment. Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been completed at least 2 days prior to enrolment and no significant toxicity are expected.
Previous radiation therapy completed =< 7 days prior to the start of study drugs
Active infection; any systemic antimicrobial therapy must be completed >= 5 days prior to initiation of protocol therapy
Patient has completed radiotherapy within 2 weeks prior to treatment initiation.
Subjects have any acute infection that requires specific therapy. Acute therapy must have been completed within seven days prior to study enrollment.
Completed planned breast surgeries and any radiation therapy >= 30 days prior to randomization
All prior systemic cancer therapy (hormonal, chemotherapeutic, and immunotherapeutic) must be completed at least 4 weeks before the baseline visit
All previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry; immunologic therapy must be completed at least 1 week prior to study entry; patients with prior stem cell transplant must be greater than 365 days post-transplant
Patients must have a histologic diagnosis of melanoma either from a primary or metastatic site; patients with brain metastases must have completed radiation therapy > 30 days prior to enrollment
Patients with a history of malignancy that has been completely treated, with no\n             evidence of that cancer currently, are permitted to enrol in the trial provided all\n             chemotherapy was completed greater than 6 months prior and/or bone marrow transplant\n             greater than 2 years prior
Patients must have successfully completed therapy with sipuleucel-T within 3-7 days of planned CYT107 study drug treatment
Prior “systemic” radiopharmaceuticals (strontium, samarium, radium 223 dichloride) must be completed >= 8 weeks prior to enrollment
Patients must be completed radiation therapy at least 4 weeks previously
Any exogenous hormone therapy must be completed 4 weeks prior to registration
Patients with prior radiation therapy completed less than 4 weeks prior enrollment
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized\r\n* For the fourth cohort, ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of BMS-936558; ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of BMS-936558\r\n* All drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 3 weeks\r\n* Patients in the fourth cohort who required infliximab or other immune suppressants including mycophenolic acid will be excluded\r\n* For the fifth cohort, ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of BMS-936558; all drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 2 weeks and any other immune suppressant such as mycophenoloc acid or infliximab for at least 3 weeks\r\n* Patients in the fifth cohort who experienced grade 3-4,neurologic or ophthalmologic side effects or any other grade 4 side effect other than liver, pancreatic, gastrointestinal (GI), endocrine, pulmonary or skin related will be excluded
Has completed a prior therapy (ies) according to the criteria below:
Patient has completed adjuvant radiotherapy (if indicated) prior to screening
Patients must have completed their last chemotherapy regimen > 4 weeks prior to treatment initiation.
Non-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusion
Will have completed the first line chemotherapy regimen completed at least 14 days prior to initiation of 2nd line chemotherapy under the protocol
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)
Prior systemic, regional and radiation anticancer therapies for melanoma must have been completed at least 3 months prior to randomization.
Completed last cycle of chemotherapy or radiation > 60 days prior to first vaccination
Prior therapy(ies), if applicable, must be completed according to the criteria below prior to first dose of tazemetostat:
Prior radiotherapy must be completed at least 4 weeks before patient begins study therapy.
Patient must have not received systemic chemotherapy for metastatic disease; prior chemotherapy, radiation therapy, concurrent chemoradiation are allowed if used for treatment of non-metastatic disease; prior palliative radiation for symptom management is allowed; any chemotherapy must have been completed 4 weeks prior to enrollment; any radiotherapy must have been completed 2 weeks prior to enrollment
Must have completed definitive resection of primary tumor. The last surgery for breast cancer must have been completed at least 14 days prior to registration for protocol therapy.
Prior chemotherapy must have been completed 21 days prior to initiation of protocol therapy and all toxicities must < grade 2.
Patients must have completed initial radiation therapy (RT) and temozolomide (TMZ) for the treatment of their glioblastoma (i.e., completed 6-week course of RT and, completed >= 75% of 6-week course of induction TMZ chemotherapy)
Any chemotherapy must have been completed 4 weeks prior to enrollment
Any radiotherapy must have been completed 2 weeks prior to enrollment
Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed
Patients must have previously received at least one line of prior systemic chemotherapy or targeted treatment for metastatic disease OR have received prior adjuvant systemic chemotherapy within prior 6 months; patients with MBC, must have received at least a taxane based regimens; patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) mutations should have failed prior standard tyrosine kinase inhibitor (TKI) therapy; patients must have completed previous treatment (including other investigational therapy) in greater than or equal to the following times prior to initiation of study treatment:\r\n* Chemotherapy/targeted therapy administered in a daily or weekly schedule must be completed >= 2 weeks prior to study treatment \r\n* Chemotherapy/targeted therapy administered in a 2-weekly schedule must be completed >= 3 weeks prior to study treatment\r\n* Chemotherapy/targeted therapy administered in a 3-weekly or greater schedule must be completed >= 4 weeks prior to study treatment
Patients must not have received prior systemic therapy for their advanced cancer; prior intravesical therapy completed 4 weeks prior to enrollment and adjuvant/neoadjuvant chemotherapy completed more than 6 months prior to diagnosis of advanced disease are permitted
Prior anti-cancer therapy within 4 weeks prior to study enrollment. Prior radiation therapy within 2 weeks prior to enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 2 days prior to study enrollment and no clinically significant toxicities are expected (eg, mucositis, esophagitis).
Any prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 2 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapy
Any prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 4 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapy
Patients may have received therapy for other malignancies, as long as they have completed therapy at least 6 months prior to study entry and be deemed to have a life expectancy of at least 2 years with regard to that malignancy
Prior treatment (somatostatin analogs excepted) must be completed at least 2 weeks prior to registration; in addition, prior treatment (somatostatin analogs excepted) must be completed at least 4 weeks prior to initiation of study drug; treatment-related toxicities must have improved to =< grade 1 prior to registration, with the exception of alopecia
Prior systemic anti-cancer therapy, unless administered for localized SCCHN and completed at least 6 months prior to disease recurrence
Patients must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy
Prior radiation therapy must be completed > 4 weeks prior to enrollment and the patient must have recovered from all toxicity. Prior radiopharmaceuticals (strontium, samarium) must be completed ? 8 weeks prior to enrollment.
Patients must have been treated previously with radiation therapy and treatment must have been completed at least 8 weeks prior to surgery for catheter implantation
prior immunotherapy, or prior investigational agents should be washed out 4 weeks before apheresis and must be completed 4 weeks prior to pre-infusion lymphodepletive chemotherapy.
Systemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapy
Radiation therapy to brain for DIPG that was completed at least 10 months prior to planned reirradiation
Prior radiotherapy must have been completed at least 2 weeks prior to study entry For Arm M:
Previous chemotherapy, immunotherapy, and hormone therapy must be completed at least 4 weeks prior to the administration of MLN2480 and radiation must be completed at least 3 weeks prior to the administration of MLN2480; all associated toxicity must be resolved to ? Grade 1
All standard tumor-staging procedures necessary to define baseline extracranial disease status completed =< 42 days prior to pre-registration
Completed cancer specific therapy at most 6 months prior to entry
Prior experimental systemic therapies must have been completed greater than 2 weeks prior to study entry
Any prior radiation therapy must be completed at least 4 weeks prior to registration
Subject may have received prior radiation therapy (except to inguinal region) but must have completed such therapy prior to enrollment
Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment
Chemotherapy or trastuzumab or bevacizumab in the adjuvant setting is allowed but must have been completed at least 4 weeks prior to study registration; other prior non-hormonal investigational agents in the adjuvant setting must have completed at least 4 weeks prior to study registration and should be discussed with the study principal investigator (PI)
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least six weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the PI’s discretion, and should have recovered to eligibility levels from any toxicities
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI’s) discretion, and should have recovered to eligibility levels from any toxicities
Completed the End of Study Visit in Study NEOD001-201
Radiation therapy was completed on the index vertebra(e) ? 28 days before enrollment,
Patients with a history of malignancy that has been completely treated, and currently with no evidence of that cancer, are permitted to enroll in the trial provided all chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 years prior to first day of study treatment
Chemotherapy must have been completed at least 4 weeks prior to initiation of study medication
Prior CNS directed radiation treatment completed within 3 weeks prior to registration
All prior chemotherapy completed at least three weeks before study treatment
Patients must have completed any previous surgery or radiotherapy >= 4 weeks prior to enrollment
The participant may have prior treatment for bladder tumor (excluding radiation therapy) provided that treatment:\r\n* Was completed greater than 30 days prior to the first dose of study agent
Prior radiation therapy is allowed but must have been completed >= 4 weeks prior to study entry; patients with history of prior radiation to the liver including radio-labeled microspheres cannot take part in this study
Completed at least one cycle of the treatment
Completed their last dose of chemotherapy or had their last cancer surgery more than 10 weeks, whichever came later, prior to randomization.
Have completed treatment greater than 4 weeks prior to enrollment.
Has completed the CS35 trial.
Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days before administration of T-cells; prior immunotherapy with checkpoint blockade (i.e., PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month before the T-cell infusion\r\n* Chemotherapy must have been completed at least 7 days prior to leukapheresis
Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days prior to administration of T cells; continuation of hormonal therapy (i.e. for breast cancer) is acceptable; prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T cell infusion\r\n* Chemotherapy must have been completed at least 7 days prior to leukapheresis
Prior radiation therapy completed >= 4 weeks prior to enrollment
TURBT successfully completed
Prior chemotherapy for curative intent is permitted providing the cytotoxic chemotherapy was completed >= 12 months prior to enrollment; patients must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 30 days prior to registration; patient must not have brain metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least 1 day; any radiation therapy completed prior to chemotherapy, except gamma-knife radiosurgery, 1 week prior to chemotherapy
Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago. No further anti-cancer therapy after the previous AR targeted therapy and before inclusion. Prior docetaxel in hormone sensitive setting is allowed if completed >1 year before randomization. Prior immunotherapy is allowed.
Completed 24 weeks of treatment in Protocol 8400-401
Prior chemotherapy completed at least 3 weeks prior to study enrollment
Radiation therapy and surgery must be completed 4 weeks prior to therapy, except for limited field radiation therapy, which must be completed 2 weeks before therapy.
completed all treatment and follow-up through at least 12 weeks
Radiotherapy (RT) completed within 14 days prior to the first dose of study therapy.
Anti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to </= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.
No prior systemic therapy or radiation therapy active against myeloma lasting more than four weeks duration; any prior therapy must be completed a minimum of 21 days before starting study drugs; enrollment of subjects who require radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Prior local radiotherapy is allowed if it is completed at least 4 weeks prior to the first dose of study drug and the subject has evaluable lesions not previously irradiated
Patients must have completed a course of radiation therapy and at least 2 adjuvant cycles of temozolomide for the phase 2 component.
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients who have had prior monoclonal antibody therapy must have completed that therapy at least 3 half-lives of the antibody or 6 weeks ago; patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center principal investigator (PI) after consultation with a cardiologist and if screening echocardiogram is normal
Prior treatment with an EGFR inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed >/=1 year before study enrollment
Patients are candidates for stereotactic radiosurgery as determined by the treating radiation oncologist; intra-cranial tumors must measure 4 cm or less in greatest dimension; patients may have received prior neurosurgical resection(s) of intra-cranial metastases if their operation(s) was (were) completed at least 28 days prior to starting study drug; patients may have had prior whole brain radiation therapy (WBRT) if it was completed at least 1 month prior to study enrollment
Has completed any prior radiotherapy ? 4 weeks prior to randomization
Has completed any prior hormonal therapy ? 2 weeks prior to randomization
Prior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.
Prior systemic chemotherapy must be completed > 2 weeks of radioembolization
Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1
Patients must have completed planned local therapy (i.e., definitive surgery and radiation therapy) and adjuvant chemotherapy for breast cancer prior to registration; in addition, any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline Patient Reported Outcomes (PRO) instruments (i.e., Health Assessment Questionnaire [HAQ], PROMIS Physical Function, Functional Assessment of Cancer Therapy [FACT] Breast and Endocrine Symptoms [ES], etc.) and collection of optional blood for banking for future research
Have completed all surgery, chemotherapy and/or radiation therapy within the last 2-60 months
Prior treatment with thoracic radiotherapy completed > 4 weeks and =< 9 months prior to enrollment
PHASE I: Completed primary surgery, chemotherapy, and radiation
Have completed neurotoxic chemotherapy at least 3 months prior to enrollment
Have completed active cancer treatment at least 1 year prior to study enrollment
Completed preoperative therapy and are on their presurgical rest period
Have completed primary treatments (including surgery, radiation, and chemotherapy) 1-5 years prior to recruitment
Chemotherapy has already commenced or been completed
Completed local definitive treatment (i.e., surgical treatment, chemotherapy and/or radiation therapy)
Completed a minimum of 8 years of education
Have completed all cancer treatment (including surgery, chemotherapy and/or radiation) at least 4 months prior to enrollment
YBCS: Completed treatment with surgery, radiation and chemotherapy (if applicable)
Gynecologic cancer treatment (e.g., surgery, chemotherapy, radiation therapy) was completed within 5 years prior to date of enrollment
Treatment has been completed (except hormone therapy) for >= 90 days prior to registration
Have completed treatment with surgery, radiation, and/or chemotherapy
PATIENTS: Have completed surgery with no plans for chemotherapy
Child: child is in treatment remission and has completed intensive therapy
Completed in person pre–test counseling
Have completed their course of CTX
Diagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within 2 months to 2 years
Completed treatment for stage 1-3 breast cancer at least two months but not more than 24 months prior to enrollment.
Radiation therapy (RT) completed >= 6 months
Women who have completed more than two rounds of chemotherapy
Completed all primary treatment
Completed initial regional and systemic treatment
Completed surgery
Completed active cancer treatment other than maintenance therapy >= 3 months ago
Surgical resection and axillary assessment, radiation therapy, and/or chemotherapy, as indicated, completed at least 3 months prior to enrollment
Have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as Herceptin)
Completed chemotherapy > 3 months prior to enrollment and no concurrent adjuvant therapy other than hormone manipulation therapy for breast cancer (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm whether or not she completed chemotherapy 3 months prior to enrollment, we will send a letter to her physician to confirm eligibility on this criterion)
Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks, prior to enrollment and must be in complete remission; consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy (chemo) or biological therapy
Patient must have completed cancer treatment >= 2 years prior to study enrollment
Completed appropriate surgical therapy to include:
Patients with history of cancer must be in remission, with surgery completed at least 6 months prior to enrollment and chemotherapy completed at least 1 year prior to enrollment (except for basal cell carcinoma of the skin)
Prior administration of anthracyclines is acceptable if therapy was completed > 6 months prior to study enrollment
No prior chemotherapy regimen; prior isotope therapy with strontium-89, samarium or radium-223 (RAD223) should be completed at least three months (12 weeks) prior to treatment start
Systemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapy.
Must have completed radiotherapy at least 12 months prior to entry
Completed radiation therapy
Prior chemotherapy completed < 7 days prior to planned study entry
Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 2 weeks prior to infusion of radiolabeled antibody
Bilirubin =< 1.5 x ULN, completed within 2 weeks prior to start of protocol therapy
Laboratory studies must be completed within 28 days prior to pimonidazole administration
Prior definitive radiation therapy must have been completed at least 3 weeks before study drug administration
Any prior systemic therapy (e.g., chemotherapy, molecularly targeted agent, immunotherapy, etc.) or major surgery must have been completed at least 30 days (or as determined by the local requirement, whichever is longer), or at least 5 half lives for drugs with half lives of 6 days or longer prior to initiation of crizotinib treatment. Any prior radiation (except palliative) or minor surgeries/procedures must have been completed at least 2 weeks prior to the initiation of crizotinib treatment. Palliative radiation (? 10 fractions) must have been completed 48 hours prior to the initiation of crizotinib treatment. Any acute toxicity must have recovered to Grade ?1 (except alopecia).
Patient: Has completed surgical therapy
Colonoscopy not completed in the last 10 years
Sigmoidoscopy not completed in the last 5 years
Colonoscopy completed within the last 10 years
Sigmoidoscopy completed within the last 5 years
Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
Glioma patients must have completed chemoradiotherapy at least 12 weeks prior to screening and their baseline scan
External beam radiation therapy within 4 weeks of registration
If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of external beam radiation therapy (EBRT) should have resolved
Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show subsequent evidence of substantial size increase to be deemed a target lesion
Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks
Subjects with TiNHL are eligible if they have received no prior cytotoxic chemotherapy for lymphoma. Steroids, rituximab, and external beam radiation therapy as prior therapy for indolent lymphoma is allowed.
Lesions that have had definitive external beam radiotherapy or locoregional therapies such as radiofrequency (RF) ablation or brachytherapy must show evidence of progressive disease to be deemed a target lesion
Prior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 Gy
Scheduled to receive a continuous course of fractionated, conventional external beam with a cumulative radiation dose between 55 and 72 Gy at each site
Any external beam radiation treatment for hepatic disease; prior external beam radiation therapy to more than 25% of the bone marrow\r\n* Prior systemic peptide receptor radionuclide therapy (PRRT) treatment is allowed, if it was performed at least six months prior
Prior history of external beam radiotherapy >= 5,000 cGy delivered to the tumor at least 4 weeks prior to Office for Human Research Studies (OHRS) registration
received external beam radiation therapy within 4 weeks
Neoadjuvant Chemordiation was administered as IMRT or 3DCRT wPreoperative External beam dose (NCCN)
external beam radiation within 2 weeks of enrollment
Any major surgical procedures or external beam radiotherapy within 14 days prior to study drug administration
The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to C1D1
Received prior external beam radiation therapy for another reason to > 25% of active bone marrow
Prior external beam radiation therapy to the target lesion(s) within 1 month prior to enrollment
Received external beam radiotherapy within the 4 weeks prior to randomization
Has an immediate need for external beam radiotherapy
Prior radiation: Patients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least 4 weeks prior to and no later than 14 weeks from the first CED treatment. Standard focal radiation therapy will include 54 to 60 Gy by external beam radiotherapy to the brainstem.
Patients who had clinical and/or radiographic (MRI) progression of tumor following external beam radiation therapy.
Has had prior thermal ablation, embolotherapy, radioembolization, or external beam radiation
Subjects must have received definitive therapy with curative intent, which consist of at least 4 weeks of treatment with cisplatin and a minimum of 40Gy external beam radiation therapy (EBRT).
Two progressive scans at least 4 weeks apart after the completion of standard external beam radiation therapy and temozolomide
Prior history of brain SRS, (patients who have received external beam radiation per standard of care are allowed)
External beam radiation to both kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Prior treatment must include external beam radiation, radiosurgery, or combination of both
External beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol
Have at least one site of lymphomatous disease amenable to external beam radiation therapy (EBRT)
Prior external beam radiation therapy to the liver (defined as > 1 gray [Gy])
external beam radiation within 2 weeks of enrollment
Patients with tumors of the brain must have been previously treated with surgical resection, external beam radiation, and temozolomide chemotherapy
Patients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least 4 weeks prior to and no later than 14 weeks from the first CED treatment with liposomal irinotecan; standard focal radiation therapy will include 54 to 60 Gy by external beam radiotherapy to the brainstem
Prior external beam radiation involving kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Prior external beam radiation (including brachytherapy) involving 25% of bone marrow (excluding scatter doses of =< 5 Gy)
Subject has received treatment with a systemic therapeutic radioisotope (89Sr, 223Ra dichloride, 153Sm-lexidronam) or has received prior external beam radiation therapy (EBRT) of the head and/or neck
Prior external beam radiation to the liver
Past history of external beam radiotherapy within the projected treatment field of any of the disease sites to be treated by MRI-guided, online adaptive SBRT
Histologically proven persistent or recurrent adenocarcinoma of the prostate following prior external beam radiation therapy
Prior whole brain radiotherapy or conventional external beam radiotherapy
PHASE I AND PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Is =< 12 weeks from completing external beam radiotherapy; patients with proven progressive disease (PD) by resection or with new lesions outside of the radiation field should not be excluded even if they are within 12 weeks of external radiation therapy (XRT), per Response Assessment in Neuro-Oncology (RANO) criteria for early PD
External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
Any contraindication to external beam radiotherapy
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must have subsequently grown unequivocally to be deemed a target lesion.
Must not be receiving external beam radiation therapy at the time of study enrollment; must be at least 12 weeks from prior I131 MIBG therapy
Definitive local treatment for primary tumor, including surgical resection (enucleation) or radiation therapy (radioactive plaque or external proton beam)
Prior upper abdominal external beam irradiation
Patients must have discontinued all previous external beam radiation therapy and recovered from side effects due to radiation therapy for more than 14 days starting on treatment
Patient must not have had prior external beam radiation to the liver
Clinical and/or radiographic (MRI) progression of tumor following external beam radiation therapy
High-dose chemotherapy or external beam radiation therapy to lung, liver, or kidneys > 20 Gy within the previous 100 days prior to therapeutic 90Y-ibritumomab tiuxetan dose
External beam radiation therapy =< 28 days prior to registration; note: previous treatment with radiation is allowed if the investigator judges it will not compromise patient safety on the study
Patients in Stratum A, B, and E must have received standard involved field radiation therapy (RT) defined as fractionated external beam radiotherapy with total doses between 5000-6000 centigray (cGy); patients in these strata must be registered within 4-12 weeks of completing RT
The patient has decided to undergo external beam radiation as treatment choice for his prostate cancer
Patients must have received prior external beam radiotherapy and temozolomide.
Participant is a candidate for, and agrees to receive conventional external beam radiotherapy
History of external beam radiation therapy to metastatic sites within 1 year of enrollment to the study
No external beam radiation therapy within 2 weeks of first vaccine administration
Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
Prior external beam radiation treatment to the liver
Lesions that have had external beam radiotherapy or locoregional therapies such as radiofrequency ablation must show evidence of subsequent progressive disease (substantial size increase of ? 20%) to be deemed a target lesion.
The patient has decided to undergo external beam radiation as treatment choice for his prostate cancer
Prior external beam radiation treatment to the liver or abdomen
Prior hemibody external radiation. Any external radiation therapy must have been completed at least 14 days prior to registration. Any toxicity from such therapy must have recovered to ? grade 1 per CTCAE version 4 criteria by the time of registration.
External beam radiation to both kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Previous treatment with external beam radiation
The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 14 days prior to study therapy administration (42 days for prior nitrosourea or mitomycin-C; patients with advanced prostate cancer who are receiving LHRH agonists are permitted onto the study and should continue use of these agents during study treatment).
> 20% bone marrow external beam radiotherapy and/or previous radioisotope therapy
The target lesions have not previously been treated with external beam radiation; the patient may have previously been treated with external beam radiation therapy to other body sites, as long as the target osseous lesions were not included in that treatment
Participants must have had their last fraction of external beam radiation therapy at least 4 weeks prior to enrollment
Completed standard external beam radiation with temozolomide
Prior external beam radiation therapy to the liver
Patients who have had external beam radiotherapy, cytotoxic chemotherapy, or oral multikinase inhibitors within 4 weeks prior to study enrollment
External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
Cohort 2: Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed >= 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression
Prior external beam radiation therapy to more than 25% of the bone marrow.
Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies
Patients with stable brain metastasis are eligible provided they received definitive therapy (external beam radiation therapy [EBRT], gamma knife, surgery) no sooner than 14 days prior to registration and are off all steroids
Any prior external beam radiation to the pelvis
Prior external beam radiation therapy completed < 3 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug.
Prior external beam irradiation to a field that includes more than 30% of the red bone marrow.
Prior external beam radiation therapy to the liver
Patients with intraocular retinoblastoma, unilateral or bilateral, who would be treated either by systemic chemotherapy, external beam radiation (EBR), or enucleation would be considered for this study
Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug
Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria
Prior external beam radiation therapy to the liver
Has received any external radiation therapy within 28 days prior to enrollment.
Received external beam radiotherapy within 4 weeks prior to registration
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of subsequent progressive disease (substantial size increase of ?20%) to be deemed a target lesion.
Has planned external beam radiotherapy (+/- chemotherapy) for 6-7 weeks
Current diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam radiation therapy (RT) to the abdomen or pelvis to a minimum dose of 4500 cGy is planned
Treatment plan that includes external beam radiation at a mean dose of at least 24 Gy or more to one of the parotid glands (the other gland can receive less than 24 Gy)
Patient has received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug
Patients must not be planning to receive concurrent external beam radiation therapy, including prophylactic cranial radiation
Treatment plan that includes external beam radiation at a mean dose of at least 24 Gy or more to one of the parotid glands (the other gland can receive less than 24 Gy)
Must have received external beam radiation with curative intent
Planning to undergo proton beam radiation therapy as part of the clinical management of the diagnosed cancer
SUB-STUDY II: Planned salvage external beam radiation therapy
Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.
Patients with lung cancer visible on CT who are scheduled to receive external beam radiation treatment will be eligible for this study
Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation or chemoembolization must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
Patients who are to receive 30 Gy or more of external beam radiation therapy.
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
Participants who have received any other investigational agents within the 4 weeks prior to enrollment; concurrent radiation therapy is not permitted, except palliative (limited-field) radiation therapy, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
Patients may not have had any prior systemic treatment for this malignancy (for example chemotherapy or somatostatin analogues); prior palliative radiation is permitted but radiated lesions may not be used for measurement
Prior palliative radiation treatment for metastatic disease to be treated on the protocol (including radiopharmaceuticals)
Participants receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used); the patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with olaparib and temozolomide
Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 42 days from the completion of radiation therapy to study entry; Note: patients with an indication for craniospinal radiotherapy (i.e., extensive leptomeningeal disease) but have refused palliative craniospinal radiotherapy are eligible
Prior palliative radiotherapy must have been completed at least 2 weeks prior to study entry
Palliative radiotherapy within 14 days before initiation of study treatment
Any major surgery, chemotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed >= 2 weeks); concurrent hydroxyurea is allowed if less than or equal to 2 grams daily and on stable dose for >= 14 days prior to study entry
Prior palliative radiation must have been completed at least 2 weeks prior to study entry
Participants who received prior non-central nervous system (CNS) directed palliative radiation therapy within 7 days of the date of study entry
Palliative radiation therapy may have been received but not within the 30 days prior to study treatment
Concurrent use of hypoglycemic agents or any systemic therapy for melanoma; palliative limited-field radiation therapy will be allowed
Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal palliative radiation to treat cancer-related pain is permitted provided that the last treatment with radiation is at least 14 days prior to Cycle 1, Day 1.
Completed palliative radiotherapy within 7 days of the first dose of study drug.
XRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
Radiotherapy within 4 weeks prior to therapy except palliative radiation to target organs other than primary tumor may be allowed up to 2 weeks prior to registration
Radiation therapy (palliative setting is allowed.): ?4 weeks
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Is eligible for palliative radiotherapy as determined by the treating radiation oncologist.
Lesion that is amenable to palliative radiotherapy
At least 2 weeks after any prior palliative radiation (e.g. to focal metastatic lesion such as bone metastases) and recovery to =< grade 1 treatment-related toxicity
Radiotherapy: ?4 weeks (patients who receive palliative radiation for nontarget tumour lesions need not be subjected to this washout period and can be enrolled immediately)
Prior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least 2 weeks prior to treatment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of first treatment are strongly encouraged to receive palliative radiotherapy prior to treatment
Patients who had undergone any palliative radiation within 2 weeks of study enrollment
Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Subjects who had major surgery or radiation therapy within 4 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass.
Subjects must have progression within 6 months of platin exposure during definitive or palliative therapy.
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment initiation
If palliative radiotherapy administered, completion of palliative radiation therapy must be >= 2 weeks prior to cycle 1 day 1 of protocol therapy
At least one tumor for which palliative RT is considered appropriate standard therapy (cohort 1); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort 2)
Prior palliative radiotherapy must have been completed at least 2 weeks prior to registration; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of randomization are strongly encouraged to receive palliative radiotherapy prior to randomization
Subjects requiring palliative radiation therapy at presentation
Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy other than palliative radiation for medical emergencies (like cord compression), within the last 4 weeks
Emergent need for palliative radiation
Palliative surgery and/or radiation treatment within 28 days prior to course 1 day 1 (C1D1) \r\n* Localized therapy of non-target lesions is allowed
Prior definitive radiation therapy must have been completed at least 4 weeks before study drug administration; prior palliative radiotherapy should be completed at least 2 weeks before study drug administration; whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) and focal radiation to the sites of pain or bronchial obstruction will be considered palliative; no radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration
Need for urgent palliative intervention (e.g., impending herniation)
Prior systemic therapy, radiation therapy, or surgery within the 28 days of starting study treatment; palliative radiotherapy to a limited filed or palliative cryoablation is allowed after consultation with the principal investigator, at any time during the study participation including screening
Radiation therapy for treatment of the primary tumor within 6 weeks of cycle 1, day 1; patients who have received palliative radiation to a single site and recovered are eligible
Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study treatment;
Radical radiotherapy to the thorax with curative intent within 28 days of initiation of study drug treatment; palliative radiotherapy for bone lesions outside of the thorax or brain within 14 days of the first dose of study treatment; palliative radiotherapy to the brain or thorax within 28 days of the first dose of study drug treatment
Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study treatment; the patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug
Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug
Patients must have histologically or cytologically confirmed advanced, incurable cancers of the esophagus, liver, stomach, small bowel, pancreas, bile duct, colon or rectum and be eligible to receive chest, abdominal and/or pelvic radiation therapy (RT) for palliation; documentation of this is required in physician note; concomitant systemic therapy is not allowed during administration of palliative RT; palliative RT can be considered for advanced primary tumors or metastatic disease as above
Radiotherapy within 4 weeks prior to enrollment, except as follows:\r\n* Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to enrollment, and\r\n* Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor-investigator prior to enrolling
Patient must be 4 weeks off any palliative radiation or craniospinal radiation
Metastatic cancer requiring palliative radiation therapy
Palliative radiation is allowed to sites that will not be used to measure response during this study
XRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
Any concurrent therapy for cancer, radiation, or surgery within 4 weeks, except for minor palliative intent (this is to be discussed with sponsor)
Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.
Localized palliative radiation therapy is allowed for symptom management if completed >= 14 days prior to randomization
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Any radiotherapy within 3 weeks except palliative stereotactic body radiation therapy (SBRT) within 2 weeks
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.
Radiotherapy (except for palliative reasons) the previous two weeks before.
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 3 weeks earlier; patients who have had prior pelvic radiation may be at increased risk for bowel perforation, and therefore may not have residual inflammatory disease of the bowel or residual bowel toxicity based on baseline imaging and clinical assessment; palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion\r\n* Bowel toxicity is not expected from the target field due to increased risk of perforation
Palliative radiotherapy (? 10 fractions) within 2 weeks prior to Screening
Palliative radiotherapy for bone metastases < 2 weeks prior to cycle 1, day 1
Prior palliative radiation therapy to bony metastases is allowed; there should be a minimum of 14 days between the end of radiation treatment and start of study treatment
Subjects who received palliative radiotherapy ?2 weeks of study drug initiation.
discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least 2 weeks prior to randomization and recovered from the acute effects of therapy
Prior palliative radiation therapy to bony metastases will be allowed; there should be minimum of 14 days between the end of radiation treatment and start of study treatment
Palliative radiation therapy to bony metastases </= 2 weeks before study treatment
Completed palliative radiotherapy within 7 days of the first dose of study medication.
Palliative radiation therapy within 2 weeks of Day 1 of trial drug treatment
Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1;
Any cancer therapy in the last 3 weeks or limited palliative radiation <2 weeks
Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, or
Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
Surgery or definitive radiation within the four weeks prior to D1 of treatment under this protocol (there is no restriction on timing of palliative radiation)
No prior palliative chemotherapy
Presence of metastatic disease that, in the opinion of investigators, would require palliative treatment within 4 weeks of enrollment
Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapy
Prior palliative radiotherapy to metastases
There should also be a minimum of 4 weeks from any prior radiotherapy except for palliative bone directed therapy
Palliative radiation must have been completed 2 weeks prior to the initiation of study therapy.
At least one tumor for which palliative RT is considered appropriate standard therapy
At least one tumor for which palliative RT is considered appropriate standard therapy (cohort 1); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort 2)
Has received anticancer chemotherapy, surgical treatment, and/or radiation therapy (except palliative radiation therapy for disease-related pain with a consult with the sponsor's medical monitor) within ?2 weeks of first study treatment.
Patients who have received palliative radiotherapy within 4 weeks of study entry.
Radiation oncologist determines that the patient is medically able to undergo palliative radiation therapy and plans to treat the patient’s target lesions with one fraction of high dose palliative radiation therapy utilizing the Scan-Plan-Quality Analysis (QA)-Treat STAT RAD workflow
Palliative radiation within 2 weeks.
Radiotherapy (except for palliative reasons), targeted therapy, or immunotherapy (except for uveal melanoma) the previous four weeks before study treatment.
Radiotherapy, chemotherapy or immunotherapy within 4 weeks, or palliative radiation to bone metastases within 14 days of administration of cycle 1, day 1
Palliative radiotherapy must have been discontinued 1 week prior to treatment in this study
No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Prior palliative radiation therapy to bone sites is allowed as long as it is completed more than two weeks ago
Rapidly progressing cancer likely to require palliative systemic intervention within 8 weeks after study entry
Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ? 2 weeks);
Patients receiving palliative radiation will be eligible after a wash-out period of 2 weeks between finishing radiation and initiation of study drugs; palliative radiation will not be allowed during cycle 1 of treatment but is permitted in this study during following cycles as long as there are evaluable lesions that are not being irradiated
No radiotherapy within 2 weeks: exception: patients may receive palliative low dose radiotherapy (30 Gy or less) for lesions outside the lung at the discretion of the treating physician; palliative radiotherapy could be given before aerosol treatment is started if necessary
No concomitant anti-cancer chemotherapy or other systemic drugs; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
At least one measurable site of disease (>= 1.5 cm) outside of the planned palliative radiation therapy field
Women with planned treatment of palliative radiotherapy
Palliative radiation to bony metastases within 2 weeks prior to initiation of ipatasertib
Subjects receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment;
Patients may receive palliative radiation therapy before or during treatment on protocol, provided that there is measurable or evaluable disease out of the radiation field; patients may receive palliative radiation therapy, if needed, 48 hours after last dose of investigational drug; in addition patients may be enrolled on trial seven days following palliative radiation; we will closely monitor for the appearance of radiation recall reactions; hormonal therapy may continue in patients who have been on such treatment for three months or longer
Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
Prior palliative radiotherapy to non-central nervous system (CNS) lesions must have been completed at least 2 weeks prior to enrollment; subjects with symptomatic tumor lesions at baseline that may require palliative radiotherapy within 4 weeks of enrollment are strongly encouraged to receive palliative radiotherapy prior to enrollment
Palliative radiation therapy within 2 weeks of Day 1, or within 4 weeks of Day 1 if a radionuclide was utilized.
Palliative radiotherapy is allowed up to 2 weeks before the first RO6927005 infusion; palliative 8 Gy radiotherapy is allowed during therapy.
Patients cannot receive concomitant radiation therapy at enrollment; while on protocol limited palliative radiotherapy extending over a small bone marrow field (10%) is allowed
Localised palliative radiotherapy Prior chemotherapy must be > 6 months before screening
Palliative radiation, including whole brain radiation therapy (WBRT), is allowed prior to enrollment as long as it is completed > 2 weeks from initiation of study treatment, and provided patient has recovered from treatment toxicities to =< grade 1
Palliative radiation to bone metastases within 2 weeks prior to Day 1
Palliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1
An immediate need for palliative radiotherapy or systemic corticosteroid therapy.
Palliative surgery or radiotherapy.
Received palliative/focal radiotherapy within 2 weeks of first dose of study treatment.
Prior radiation therapy completed < 3 weeks or single fraction of palliative radiotherapy < 14 days prior to first dose of KPT-330 (selinexor)
Palliative radiation therapy to metastatic sites of disease < 2 weeks prior to study day 1.
within 2 weeks prior to the first dose of KTN3379 in the case of palliative radiation therapy.
Palliative surgery and/or radiation treatment less than 4 weeks to randomization.
Palliative radiation within 2 weeks prior to Day 1.
An immediate need for palliative radiotherapy or systemic corticosteroid therapy
Therapeutic or palliative radiation therapy within 30 days of starting treatment
Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
Received local palliative radiation therapy <14 days prior to the first dose of study medication
Palliative radiotherapy is not permitted throughout the study period;
No concomitant anti-cancer chemotherapy or other systemic drugs; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
Therapeutic or palliative radiation therapy within 2 weeks prior to enrollment
The participant has completed prior chemotherapy and/or radiotherapy with curative intent at least 3 weeks prior to the administration of the first dose of study therapy. Participants that have received palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible
Prior systemic therapy, radiation therapy, or surgery within 28 days of starting study treatment; palliative radiotherapy to a limited field or palliative cryoablation is allowed after consultation with the principle Investigator, at any time during the study participation including screening
Palliative radiation treatment (e.g., pain control, bony lesions at risk of fracture) completed =< 2 weeks of starting study treatment; patient will be eligible if palliative radiotherapy is completed > 2 weeks from the start of study treatment and has recovered from radiotherapy toxicities
All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), and surgery, >= 28 days before study entry
Undergoing only palliative (not curative) radiation treatment
Patients already receiving palliative care
PATIENT EXCLUSION: Palliative performance scale rating < 40
Palliative surgery and/or radiation treatment within 30 days prior to date of screening visit.
New systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
Patients already receiving palliative care
(Physician participation) a palliative medicine specialist
Palliative Performance Scale (PPS) of 60 or higher at recruitment
Patient is planned to receive hypofractionated palliative radiation =< 10 fractions
Previous radiotherapy or palliative surgery to the painful site that is planned for treatment
Receiving palliative radiation therapy
At least 28 days since the last chemotherapy or immunotherapy prior to the first dose; at least 14 days since the last radiation prior to the first dose (exception: palliative radiotherapy for pain can be used greater than or equal to (>=) 7 days prior to or after infusion)
At the time of day 1 of the study, patients must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, radiation therapy or major surgery (requiring general anesthesia) at least 28 days before administration of the first dose of nivolumab; patients undergoing minor surgical procedures and biopsies that do not require general anesthesia may begin receiving study therapy if sufficiently recovered as determined by the treating investigator; patients may have received prior focal radiotherapy for palliation of an isolated site of disease, which must be completed at least 14 days prior to day 1 of the study; palliative (limited-field) radiation therapy is permitted during treatment with study drug(s), if all of the following criteria are met: \r\n* The lesion being considered for palliative radiation is not a target lesion\r\n* Radiation treatment is administered 12 weeks or greater after their first dose of study drug
Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug
Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) =< 3 weeks prior to study drug administration date
Treatment with palliative or pre-operative radiation
Patient receiving palliative radiation therapy (defined as less than 45 Gy)
Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non- central nervous system (CNS) disease with medical monitor approval.
>1 week since palliative RT
Patients treated with radiation for palliative intent
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment to the site of bone and other metastasis.
Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment in Cycle 1
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment.
Has received prior radiotherapy within 2 weeks of start of study treatment.
Concurrent anticancer treatment within 28 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy]; immune therapy, or cytokine therapy, except for erythropoietin.
Patients cannot have received radiotherapy to lung fields within 6 months of study treatment start.
Patients with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e. D1 of cycle 1); however, prior surgery or radiation therapy aimed at local palliation or attempted local disease control (except in case of thoracic radiotherapy) is permitted but has to be completed one week before treatment start
Radiotherapy to multiple sites or immunotherapy within 3 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)
Has received prior radiotherapy within 2 weeks of start of trial treatment.
Has received prior radiotherapy within 2 weeks of start of study therapy
Has received prior radiotherapy within 2 weeks of start of study treatment.
Prior radiation therapy within 21 days prior to the start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start
Prior radiotherapy within 2 weeks of start of study treatment
Radiotherapy within the last 4 weeks before start of study drug treatment with the exception of limited field palliative radiotherapy for bone pain relief
Anticancer treatment within 14 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).
Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
The last dose of previous therapy must have occurred at least 3 weeks prior to the start of study therapy; palliative radiotherapy is allowed up to 2 weeks before the first LMB-100 infusion
Anticancer treatment within 14 days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).
Interval between the hysterectomy and planned start of radiotherapy exceeding 16 weeks
Hormonal treatment within 2 weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted); radiotherapy within 4 weeks prior to enrolment; palliative radiation to target organs may be allowed up to 2 weeks prior to enrolment, as long as there are other target lesions that can be monitored for response to study treatment
The last dose of previous therapy must have occurred at least 3 weeks prior to the start of study therapy; palliative radiotherapy is allowed up to 2 weeks before the first LMB-100 infusion
Has received external radiotherapy within the last 4 weeks prior to start of study treatment
Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma unless the radiotherapy was completed within28 days prior to start of study treatment. Subject who received palliative radiotherapy to peripheral bone metastases ?14 days prior to start of study treatment and has recovered from all acute toxicities is allowed.
Radiotherapy during study or within 3 weeks of start of study drug. [Palliative radiotherapy will be allowed]
Has received prior radiotherapy within 3 weeks of start of study treatment
Received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (?2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
Radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities.
The subject must have first vaccine treatment start date at least 4 weeks out but not more than 8 weeks from the last dose of concomitant temozolomide or radiotherapy
Has received prior radiotherapy within 3 weeks of start of study treatment; participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
Radiotherapy within 4 weeks prior to start of study treatment, except as follows:
Radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
Palliative radiotherapy completed =< 7 days from treatment start
Anticancer treatment within 28 days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy
Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to start
Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)
Prior radiotherapy within 4 weeks of the start of study drug
Patients who had radiation therapy within 28 days prior to start of study treatment (palliative radiotherapy to bone lesions allowed if completed 2 weeks prior to study treatment start)
Palliative radiotherapy (to bone or soft tissue lesions) must be completed >2 weeks prior to start of study drug.
Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start
Radiotherapy to the target lesions within 3 weeks of start of first dose. Toxicities from radiotherapy must have resolved prior to start of first dose.
Subjects who have had surgery/radiotherapy within 2 weeks prior to start of study
Radiotherapy within 3 weeks prior to start of treatment
Radiotherapy within 4 weeks prior to the start of study treatment
Radiotherapy within 4 weeks before start of study treatment
Has received prior radiotherapy within 2 weeks of start of study treatment for any other condition.
Requirement for immediate palliative treatment of any kind including surgery
No requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Requirement for immediate palliative treatment of any kind including surgery
Able to discontinue all anticancer therapies 2 weeks prior to study start
Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics). Patients who have received prior endocrine therapy for fertility purposes will be eligible
Radiotherapy - 2 weeks NOTE: Duration of any other anticancer therapies must be discussed with the Sponsor Study Physician
Subjects previously treated with investigational anticancer therapies less than 6 weeks prior to the first dose of Nivolumab
Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics)
Subjects currently receiving other anticancer therapies.
Patients currently receiving medical anticancer therapies or who have received medical anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within 30 days of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.); steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapy
Received any other investigational therapeutic agents or other anticancer therapies within 4 weeks prior to randomization
Patients currently receiving anticancer therapies or who have received anticancer therapies (including chemotherapy and targeted therapy) within 2 weeks (14 days) prior to study day are excluded. Patients who have completed palliative radiation therapy more than 14 days prior to the first dose of the combination ipilimumab plus nivolumab are eligible.
Fewer than 28 days from prior anticancer therapy including chemotherapy, hormonal, investigational, and/or biological therapies and irradiation except for:
MCL requiring treatment and for which no prior systemic anticancer therapies have been received.
Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks (14 days) from enrollment into this study (including chemotherapy and targeted therapy) are excluded; also, patients who have completed palliative radiation therapy more than 14 days prior to the first dose of MGCD516 are eligible
Subjects may not be receiving any other investigational agents or anticancer therapies.
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of the investigational therapy (including chemotherapy, radiation therapy, antibody based therapy)
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks including chemotherapy, radiation therapy, antibody based therapy, etc.
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving non-hormonal anticancer therapies or who have received non-hormonal anticancer therapies within 4 weeks from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received exclusively for bony metastases and the interval between completion of radiation treatments and the first infusion of study drug is less than 7 days; hormonal therapies are not excluded
Current or recent treatment with biologic anticancer therapies
Ongoing AEs from prior anticancer therapies
Patients currently receiving anticancer therapies or who have received anticancer therapies within 28 days from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received for bone metastases (palliative radiation), the minimum interval between completion of radiation treatment and first dose of study drug is 14 days
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies =< 4 weeks prior to registration (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy)
Insufficient recovery from all side effects of previous anticancer therapies
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus and LDE225 (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug including chemotherapy, biologics, targeted therapies, or immunologics
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug or patients receiving prior treatment with investigational drugs 4 weeks of the start of study drug
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Anticancer chemotherapy or immunotherapy during the study or within less than 3 half-lives for anticancer chemotherapy or 6 weeks for antibody therapies (2 weeks for leukemia patients) prior to start of study drug.
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc., but not including somatostatin analogues, e.g., octreotide)
Anticancer treatment with radiation therapy, targeted therapies, chemotherapy, immunotherapy, hormones or other antitumour therapies within 28 days prior to first dose of TH-302.
Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
Patients currently receiving any other anticancer therapies;
Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc)
Patients currently receiving anticancer therapies (except biphosphonate, denosumab);
Autologous HSCT within six weeks prior to start of AMG 673 treatment.
Allogeneic HSCT within three months prior to start of AMG 673 treatment.
Prior HDT with autologous HSCT
Autologous HSCT within six weeks prior to start of AMG 330 treatment
Allogeneic HSCT within three months prior to start of AMG 330 treatment
Patients with aggressive NHL must have failed autologous hematopoietic stem cell transplantation (HSCT), or are ineligible or not consenting to autologous HSCT
Alemtuzumab treatment within 8 weeks of HSCT admission
Hodgkin lymphoma\r\n* Primary treatment failure ineligible for autologous HSCT\r\n* Relapse/progression after autologous HSCT
Relapsed post-autologous HSCT
Has received autologous HSCT within 6 weeks prior to start of treatment. Other Exclusion Criteria May Apply.
Alemtuzumab treatment within 8 weeks of HSCT admission
Hodgkin’s lymphoma\r\n* Primary treatment failure ineligible for autologous HSCT; relapse/progression after autologous HSCT
Treatment plan including autologous HSCT
Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning